• 1. Time sensitive, temperature and pH responsive photoluminescence behaviour of a melamine containing bicomponent hydrogel
  Bappaditya Roy,Abhijit Saha,Aluri Esterrani,Arun K. Nandi Soft Matter 2010 6 3337
• 2. A light harvesting Bi-component hydrogel with a riboflavin acceptor
  Partha Bairi,Bappaditya Roy,Arun K. Nandi Chem. Commun. 2012 48 10850
• 3. Amine functionalized MCM-41: an efficient heterogeneous recyclable catalyst for the synthesis of quinazoline-2,4(1H,3H)-diones from carbon dioxide and 2-aminobenzonitriles in water
  Deepak B. Nale,Surjyakanta Rana,Kulamani Parida,Bhalchandra M. Bhanage Catal. Sci. Technol. 2014 4 1608
• 4. Supramolecular and suprabiomolecular photochemistry: a perspective overview
  Sharmistha Dutta Choudhury,Haridas Pal Phys. Chem. Chem. Phys. 2020 22 23433
• 5. Efficient synthesis of quinazoline-2,4(1H,3H)-diones from CO2 using ionic liquids as a dual solvent–catalyst at atmospheric pressure
  Wenjing Lu,Jun Ma,Jiayin Hu,Jinliang Song,Zhaofu Zhang,Guanying Yang,Buxing Han Green Chem. 2014 16 221

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Recent Advances in the Study of 6,7-Dimethoxyquinazoline-2,4-dione (CAS: 28888-44-0) in Chemical Biology and Pharmaceutical Research

6,7-Dimethoxyquinazoline-2,4-dione (CAS: 28888-44-0) is a quinazoline derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by its dimethoxy substitution at the 6 and 7 positions, has been explored for its diverse biological activities, including antitumor, antimicrobial, and anti-inflammatory properties. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and evaluating its efficacy in various preclinical models.

One of the key areas of research has been the compound's role as a kinase inhibitor. Kinases are critical targets in cancer therapy, and 6,7-Dimethoxyquinazoline-2,4-dione has shown promising inhibitory effects on several kinases involved in cell proliferation and survival. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits selective inhibition against EGFR (Epidermal Growth Factor Receptor) mutants, which are often implicated in non-small cell lung cancer (NSCLC). The study highlighted the compound's ability to bind to the ATP-binding site of the kinase, thereby disrupting its activity.

In addition to its kinase inhibitory properties, 6,7-Dimethoxyquinazoline-2,4-dione has also been investigated for its antimicrobial potential. A recent study in the European Journal of Medicinal Chemistry reported its efficacy against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compound's ability to interfere with bacterial cell wall synthesis, a mechanism distinct from that of conventional antibiotics. These findings suggest that 6,7-Dimethoxyquinazoline-2,4-dione could serve as a scaffold for developing novel antimicrobial agents.

The synthetic chemistry of 6,7-Dimethoxyquinazoline-2,4-dione has also seen advancements. Traditional synthetic routes often involved multi-step processes with low yields, but recent work has focused on streamlining these methods. A 2022 publication in Organic Letters described a one-pot synthesis approach that significantly improved yield and reduced reaction time. This methodological innovation is expected to facilitate large-scale production and further pharmacological evaluation of the compound.

Despite these promising developments, challenges remain. The pharmacokinetic properties of 6,7-Dimethoxyquinazoline-2,4-dione, such as its solubility and metabolic stability, need further optimization to enhance its bioavailability. Additionally, more in vivo studies are required to validate its therapeutic potential and assess potential toxicity. Nevertheless, the compound's multifaceted biological activities and recent synthetic advancements position it as a valuable candidate for future drug discovery efforts.

In conclusion, 6,7-Dimethoxyquinazoline-2,4-dione (CAS: 28888-44-0) represents a versatile scaffold with significant potential in chemical biology and pharmaceutical research. Ongoing studies continue to uncover its mechanisms of action and expand its therapeutic applications, making it a compound of great interest to researchers in the field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)